A systematic review conducted by Cramer in the United States assessed patients with diabetes’ adherence with oral hypoglycemic agents and insulin and reported that 36% to 93% of the patients taking OHA remained on their treatment for 6-24 months. The gene discussed is INS; the disease is diabetes mellitus.